Questions and answers
19 November 2020
KEY LEARNINGS FROM AUSTRALIA’S HPV VACCINATION EXPERIENCE
Dr Julia BrothertonMedical Director, Population Health
VCS Foundation, Melbourne, Australia
Australia is in its 14th year of HPV vaccination, which started with a catch-up programme. Before 2018, the programme used three-dose quadrivalent HPV vaccine, with male vaccination commencing in 2013. Since 2018, the routine school-based programme has used two-dose nonavalent vaccine. This presentation assesses whether Australia’s coverage, and programme impacts so far, are consistent with achieving elimination of cervical cancer in Australia.
KEY TRENDS IN HPV VACCINATION FROM A GLOBAL PERSPECTIVE
Mr Paul BloemHPV Vaccine Strategy Lead
World Health Organization, Geneva, Switzerland
How have other countries followed Australia’s example, and what has been learned about HPV vaccination in lower-resource settings? An overview of introduction status by region and income levels points to both challenges and successes, followed by an assessment of the key drivers affecting introductions in the coming years. Against the goal of eliminating cervical cancer, Paul assesses the feasibility of reaching global cervical cancer elimination targets, and discusses possible future innovations in HPV vaccination programmes.
Dr Gary CliffordHead of the Infections and Cancer Epidemiology Group
International Agency for Research on Cancer, Lyon, France